CDDP ((SP-4-2)-diamminedichloroplatinum (II)) is an alkylating agent that has been used in the treatment of a wide assortment of cancers [17-19]. First Food and Drug Administration (FDA) approved in 1978, CDDP remains the most effective choice of platinum-based chemotherapeutics. Its mechanism of action first involves CDDP entering the cell via both active and passive transport [20,21]. Upon entering the nucleus, CDDP loses its two chlorine atoms and binds to the nitrogen atoms of two consecutive purine bases on the deoxyribonucleic acid (DNA), forming CDDP-DNA cross-linked adducts. These adducts cause a conformational change in the DNA, allowing for the binding of high mobility group domain proteins. Once bound, high mobility group proteins destabilize the base pairs beyond reparation, halting DNA transcription and replication, ultimately inducing apoptosis . Despite its proven efficacy when dosed properly, the dosing options of IV CDDP in patients are often limited to suboptimal treatment levels due to systemic toxicity and severe side effects. These side effects include nausea and vomiting, anemia, mucositis, ototoxicity, neurotoxicity, and nephrotoxicity [23,24]. Additionally, once in the bloodstream CDDP faces two significant issues: (a) CDDP is subject to chemical deactivation by substitution or elimination of amine groups , and (b) being a nontargeted molecule, only a fraction of CDDP actually reaches the tumor site. This can be attributed to the small size of CDDP molecules, which allows them to easily diffuse through a tumor's malformed and permeable vasculature  rather than remain local.